Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Venetoclax in Acute Myeloid Leukemia: NCT07451912 Clinical Landscape Report 2026
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07451912 Clinical Landscape Report 2026
28 September 2026
NCT07451912 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Venetoclax in Acute Myeloid Leukemia: ACTRN12626000278336 Clinical Landscape Report 2026
9 min read
Venetoclax in Acute Myeloid Leukemia: ACTRN12626000278336 Clinical Landscape Report 2026
28 September 2026
ACTRN12626000278336 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Betamethasone in Psoriasis of nail: PACTR202603828332085 Clinical Landscape Report 2026
9 min read
Betamethasone in Psoriasis of nail: PACTR202603828332085 Clinical Landscape Report 2026
28 September 2026
PACTR202603828332085 clinical landscape for Psoriasis of nail: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
AVA-6103 in Locally Advanced Malignant Solid Neoplasm: NCT07454642 Clinical Landscape Report 2026
9 min read
AVA-6103 in Locally Advanced Malignant Solid Neoplasm: NCT07454642 Clinical Landscape Report 2026
28 September 2026
NCT07454642 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
DS-234 in Eczema: NCT07453602 Clinical Landscape Report 2026
9 min read
DS-234 in Eczema: NCT07453602 Clinical Landscape Report 2026
28 September 2026
NCT07453602 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
S-4321 in Lupus Erythematosus, Cutaneous: NCT07455578 Clinical Landscape Report 2026
9 min read
S-4321 in Lupus Erythematosus, Cutaneous: NCT07455578 Clinical Landscape Report 2026
28 September 2026
NCT07455578 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ivosidenib in Acute Myeloid Leukemia: NCT07463768 Clinical Landscape Report 2026
9 min read
Ivosidenib in Acute Myeloid Leukemia: NCT07463768 Clinical Landscape Report 2026
28 September 2026
NCT07463768 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ruxolitinib Phosphate in Relapsing acute myeloid leukemia: NCT07464951 Clinical Landscape Report 2026
9 min read
Ruxolitinib Phosphate in Relapsing acute myeloid leukemia: NCT07464951 Clinical Landscape Report 2026
28 September 2026
NCT07464951 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
Bevacizumab in Ovarian Cancer: NCT07472140 Clinical Landscape Report 2026
9 min read
Bevacizumab in Ovarian Cancer: NCT07472140 Clinical Landscape Report 2026
28 September 2026
NCT07472140 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Famitinib Malate in Uterine Cervical Cancer: NCT07466901 Clinical Landscape Report 2026
9 min read
Famitinib Malate in Uterine Cervical Cancer: NCT07466901 Clinical Landscape Report 2026
28 September 2026
NCT07466901 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
CD84 Targeted CART(Gyala Therapeutics) in Acute Myeloid Leukemia: NCT07471789 Clinical Landscape Report 2026
9 min read
CD84 Targeted CART(Gyala Therapeutics) in Acute Myeloid Leukemia: NCT07471789 Clinical Landscape Report 2026
28 September 2026
NCT07471789 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Benmelstobart in Recurrent Cervical Cancer: NCT07472153 Clinical Landscape Report 2026
9 min read
Benmelstobart in Recurrent Cervical Cancer: NCT07472153 Clinical Landscape Report 2026
28 September 2026
NCT07472153 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →